Shuying Ye

Shuying Ye

Auto-generated profile, based on publicly available information

Shuying Ye

Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Guangdong-Hong Kong Joint Laboratory for RNA Medicine, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 December 2023 in Nature
Verified
Journal Article
Closed access
PDF file
DHDi Huang
Di Huang
XZXiaofeng Zhu
Xiaofeng Zhu
SYShuying Ye
Shuying Ye
JZJiahui Zhang
Jiahui Zhang
JLJianyou Liao
Jianyou Liao
ESErwei Song
Erwei Song

22 November 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
XCXueman Chen
Xueman Chen
RLRong Luo
Rong Luo
YZYunmei Zhang
Yunmei Zhang
SYShuying Ye
Shuying Ye
XZXin Zeng
Xin Zeng
ESErwei Song
Erwei Song
Aromatase inhibition is an efficient endocrine therapy to block ectopic estrogen production for postmenopausal estrogen receptor (ER)-positive breast cancer patients, but many develop resistance. Here, we show that aromatase inhibitor (AI)-resistant breast tumors display features of enhanced aerobic glycolysis with upregulation of long noncoding RNA (lncRNA) DIO3OS, which correlates with poor prognosis of breast cancer patients on AI therapies. Long-term estrogen deprivation induces DIO3OS expression in ER-positive breast tumor cells, which further enhances aerobic glycolysis and promotes estrogen-independent cell proliferation in vitro and in vivo. Mechanistically, DIO3OS interacts with polypyrimidine tract binding protein 1 (PTBP1) and stabilizes the mRNA of lactate dehydrogenase A (LDHA) by protecting the integrity of its 3’UTR, and subsequently upregulates LDHA expression and activates glycolytic metabolism in AI-resistant breast cancer cells. Our findings highlight the role of lncRNA in regulating the key enzyme of glycolytic metabolism in response to endocrine therapies and the potential of targeting DIO3OS to reverse AI resistance in ER-positive breast cancer.

29 September 2025 in Nature Immunology
Verified
Journal Article
Closed access
XZXiaoqian Zhang
Xiaoqian Zhang
PHPenghan Huang
Penghan Huang
HCHuiping Chen
Huiping Chen
CYChaoqun Yang
Chaoqun Yang
XYXinyu Yang
Xinyu Yang
JCJianing Chen
Jianing Chen

22 August 2024
Verified
Preprint
Open access
ZLZhihan Liu
Zhihan Liu
SYShuying Ye
Shuying Ye
ZWZhihao Wei
Zhihao Wei
SSShicheng Su
Shicheng Su
YLYiwen Lu
Yiwen Lu